Key result
Ambrisentan shows tolerable safety and symptom improvement in ~87% of real-world PAH patients.
Why the study?
This regulatory post-marketing surveillance was organized to identify the safety and effectiveness of ambrisentan in real clinical practice in the Korean population.
Does ambrisentan improve symptoms and maintain safety in Korean patients with WHO functional class II or III pulmonary arterial hypertension in real-world practice?
Observational (n=293)
Open-label
Yes
Does ambrisentan improve symptoms and maintain safety in Korean patients with WHO functional class II or III pulmonary arterial hypertension in real-world practice?
In real-world practice in Korea, ambrisentan demonstrated tolerable safety and favorable effectiveness for patients with pulmonary arterial hypertension.
Supports tolerability in Korean real-world PAH; hypothesis-generating, needs RCTs before practice change.
PURPOSE: This regulatory post-marketing surveillance (PMS) was organized to identify the safety and effectiveness of ambrisentan in the Korean population. METHOD: This was an open-label, multi-center PMS conducted from 31 institutions in Korea for 6 years from August 2015 to 2021, to evaluate the use of ambrisentan for the treatment of pulmonary arterial hypertension (PAH). Inclusion criteria are Korean subjects with the World Health Organization functional classification (WHO Fc) II or III PAH who are new users or repeated users with ambrisentan (Volibris®) Tablet 5 or 10 mg per day (age >18 years old). RESULTS: A total of 293 cases were analyzed. The overall incidence of adverse events (AE) was 52.22% and adverse drug reactions (ADR) was 10.92%. Severe AEs occurred in 20.82% of patients. However, only 2 subjects (0.68%) reported serious ADR. The difference in AE incidence was statistically significant for concomitant medications other than PAH medications in the safety analysis and the new users (p = 0.0041 and p = 0.0299, respectively) and elderly population in the repeated users (p = 0.0319). Among the long-term 223 subjects, the WHO Fc II and III were 41.26% and 58.74% before ambrisentan, and changed after treatment to 3.09%, 66.05%, and 30.86% for Fc I/II/III, respectively. 217 of 249 subjects (87.15%) considered their symptoms to have 'improved' after the last administration. CONCLUSION: In real-world practice, ambrisentan demonstrated tolerable safety and favorable effectiveness in PAH patients in Korea. Age and concomitant drug use can affect the occurrence of AE.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2023) conducted an observational in pulmonary arterial hypertension (PAH) (n=293). ambrisentan was evaluated on overall incidence of adverse events (AE). Ambrisentan demonstrated tolerable safety with an overall adverse event incidence of 52.22% and improved symptoms in 87.15% of pulmonary arterial hypertension patients in real-world practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: